RCT | Orteronel for metastatic hormone-sensitive prostate cancer.

Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216) – Journal of Clinical Oncology

Commentary: Orteronel Misses Goal in Metastatic Hormone-Sensitive Prostate Cancer – HealthDay

Commentary on Twitter

⛔ SWOG-1216: Orteronel did not improve overall survival for metastatic hormone sensitive #ProstateCancer ➡️ https://t.co/aejFNEb7bM #JCO #PCSM @theNCI @SWOG @neerajaiims @shilpaonc pic.twitter.com/LP5oHQqSIg

— Journal of Clinical Oncology (@JCO_ASCO) May 6, 2022